abstract |
The present invention provides a novel crystalline forms of sugammadex, designated herein as crystalline form Type 1 of sugammadex, crystalline form Type 2 of sugammadex, crystalline form Type 3 of sugammadex, crystalline form Type 8 of sugammadex, and crystalline form Type 9 of sugammadex, pharmaceutical compositions thereof, and methods for their use in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery. |